Retatrutide vs AOD-9604

Yes. In 2024, AOD-9604 completed a Phase 2 trial in obesity that showed no statistically significant weight loss benefit over placebo. The compound had been in clinical development on and off since the early 2000s, originally at Metabolic Pharmaceuticals, with earlier smaller trials showing modest or inconsistent effects. The 2024 Phase 2 failure was the clearest negative signal to date. Despite the result, it continues to be marketed for weight loss in the anti-aging and compounding pharmacy space.

Retatrutide hits three receptors instead of one or two. Semaglutide is a pure GLP-1 agonist. Tirzepatide hits GLP-1 and GIP. Retatrutide adds a third target: glucagon. Glucagon activation sounds counterintuitive because glucagon raises blood sugar, but paired with GLP-1 it increases energy expenditure and fat oxidation. That third mechanism is what pushed trial weight loss from ~22% on tirzepatide to 28.7% on retatrutide in Phase 3 data.

Yes, through research chemical suppliers and some compounding pharmacy pathways that predate stricter enforcement. Research-grade AOD-9604 runs $40-80 per month. The marketing continues despite the 2024 Phase 2 failure because the anti-aging and wellness ecosystem built inventory and demand before the negative data landed. Buyer should understand the current evidence base: no Phase 2 efficacy signal, no FDA approval pathway, no compelling reason to use it over an actually effective compound.

Not until 2027 at the earliest. Eli Lilly has indicated it expects to file the New Drug Application in late 2026 based on the TRIUMPH-4 data. FDA review typically runs 10-12 months, which puts the earliest realistic approval in the second half of 2027. Until then, retatrutide is only available through ongoing clinical trials or research chemical suppliers. Anyone claiming to have legitimate prescription access before NDA filing is either in a trial or lying.

Retatrutide works via Triple agonist targeting GIP, GLP-1, and glucagon receptors to enhance insulin secretion,. AOD-9604 works via Modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis. They differ in FDA approval status, efficacy data, and cost.

Retatrutide has demonstrated 28.7% average weight loss in clinical trials. AOD-9604 is not primarily used for weight loss.

Retatrutide typically costs $1,200 - $1,500/mo, while AOD-9604 costs $30 - $60/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

Retatrutide is not FDA-approved (Phase 3 (NDA expected late 2026)). AOD-9604 is not FDA-approved (Phase 2 (failed; reclassification pending)). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of Retatrutide include Nausea, Diarrhea, Vomiting. Common side effects of AOD-9604 include Injection site reactions, Headache, Chest tightness (rare). Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.